Kyverna is a clinical-stage biopharmaceutical company developing cell therapies to treat autoimmune diseases, with a focus on CAR T-cell products that target B cells to achieve long-term treatment-free remission. The company's lead candidate, mivocabtagene autoleucel (miv-cel), is an autologous, fully human CD19-targeting CAR T-cell therapy being advanced in multiple autoimmune indications including stiff person syndrome, generalized myasthenia gravis, and others, with clinical trial data demonstrating B-cell depletion and durable disease improvement. Kyverna generates value by licensing its proprietary CAR construct technology, conducting clinical trials to establish efficacy and safety, and partnering with contract manufacturers to produce its therapies; the company's business model targets the large and underserved autoimmune disease market where existing chronic therapies have limited curative potential.